The product is licensed by clients such as aging-in-place facilities, wellness-focused businesses, care management organizations, health systems, and employee benefits leaders.
Enterprises can deploy the solution for use with a general managed population or an at-risk population, such as seniors, postoperative patients, those with health conditions, or new mothers.
Through an easy-to-use dashboard, an enterprise can survey, message and educate its population while the connected mobile App empowers and engages patients/employees and their families through alerts, journals, reminders, surveys, instant messaging, and tailored content.
Research by the American Heart Association indicates that incorporating family support and providing easy-to-read educational material to patients and their caregivers enhance medication adherence.
Another element of the App is targeted educational assistance (TEA), a health condition education content that is auto-delivered to the App from sources such as the National Library of Medicine.
The App also includes features to increase medication adherence. The dashboard also contains population health analytics tools tailored to the needs of the enterprise.
ICMed is a mobile patient & family engagement solution.
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Sobi and Innate confirm strategic partnership
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease